National Survey of Precision Medicine in Cancer Treatment

The National Survey of Precision Medicine in Cancer Treatment was the first nationally representative survey of oncologists about the current practice of precision medicine in cancer treatment.

Genetic, genomic, and biomarker tests are transforming cancer care and treatment. However, the development and diffusion of gene expression profiling and next generation sequencing tests have out-paced the generation of data on their clinical utility and the development of clinical guidelines. Few studies have evaluated physicians’ experiences using genomic tests and how their experiences may differ across practice settings.

The National Survey of Precision Medicine in Cancer Treatment was fielded to better understand how oncologists use genomic testing to inform treatment recommendations; their confidence in using genomic test results to guide care; as well as key barriers, drivers, and other factors that influence their use of genomic testing in clinical practice. A nationally representative sample of 1,281 medical oncologists, hematologists-oncologists, and hematologists practicing in the continental United States participated in the survey. Data were collected from February through May of 2017.

The National Survey of Precision Medicine in Cancer Treatment was sponsored by the National Cancer Institute, with support from the American Cancer Society and National Human Genome Research Institute.

Obtain the Surveys

Copies of the National Survey of Precision Medicine in Cancer Treatment are available in PDF format. Request a copy using our Web contact form.

Last Updated: 16 May, 2019